Journal of International Oncology ›› 2019, Vol. 46 ›› Issue (10): 605-608.doi: 10.3760/cma.j.issn.1673-422X.2019.10.007

Previous Articles     Next Articles

Role of leukemia inhibitory factor in tumorigenesis and development

Si Sainyu1, Wang Huaying2, Yu Wanjun2, Li Jipeng2   

  1. 1Department of Clinical Medicine, Medical College, Ningbo University, Ningbo 315100, China; 2Department of Respiratory and Critical Care Medicine, Yinzhou Hospital Affiliated to Medical College of Ningbo University, Ningbo 315100, China

  • Online:2019-10-08 Published:2019-12-20
  • Contact: Yu Wanjun, Email: nbywj2008@aliyun.com E-mail:nbywj2008@aliyun.com
  • Supported by:
    Medical and Health Science and Technology Project  of Zhejiang Province of China (2017KY615, 2018KY749)

Abstract: Leukemia inhibitory factor (LIF) is a multifunctional secretory cytokine that plays a role in different tumor tissues and cells through janus kinase/signal transducer and activator of transcription 3, phosphatidylinositol 3kinase, mitogen-activated protein kinase signaling pathways. LIF is highly expressed in colorectal cancer, breast cancer, malignant melanoma, nasopharyngeal carcinoma and other malignant tumors. High expression of LIF can promote the development of cancer, increase the ability of tumor invasion and migration, reduce the sensitivity of radiotherapy and chemotherapy, and lead to poor prognosis. Blocking the LIF signaling pathway can inhibit tumor progression, and LIF is expected to become a new target for tumor therapy.

Key words: Neoplasms, Leukemia inhibitory factor, STAT3 transcription factor